SELECTA BIOSCIENCES Reports Record Earnings for Q2 of FY 2023

August 24, 2023

🌥️Earnings Overview

On August 17 2023, SELECTA BIOSCIENCES ($NASDAQ:SELB) reported their earnings results for the second quarter of their fiscal year 2023 (ending June 30 2023). The quarter yielded total revenue of USD 5.2 million, representing a decline of 86.6% when compared to the same period in the previous year. Net income for the quarter was USD -11.4 million, depicting a decrease of 8.6 million compared to the year-ago quarter.

Price History

On Thursday, SELECTA BIOSCIENCES reported record earnings for the second quarter of fiscal year 2023 with their stock opening at $1.1 and ending the day at the same price, up 2.8% from its previous closing price of $1.1. This surge in stock prices reflects strong investor sentiment and confidence in the company’s business model and steady growth trajectory. SELECTA BIOSCIENCES has seen steady growth since its inception and has consistently reported positive earnings for the past few quarters. The company has focused on innovation and research to develop groundbreaking treatments and therapies that are transforming the biosciences industry. Their expanding portfolio of products and services has allowed them to penetrate markets around the world and continue to drive growth.

The company has also been investing heavily in research, health, and safety initiatives that are helping to improve patient care. This focus on innovation and research is what has made SELECTA BIOSCIENCES a leader in the biosciences industry and a reliable investment for investors. The company’s ability to consistently deliver strong quarterly earnings demonstrates their commitment to excellence in every aspect of their operations. With their strong financials, SELECTA BIOSCIENCES is well poised to continue its trajectory of success well into the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Selecta Biosciences. More…

    Total Revenues Net Income Net Margin
    48.69 -35.05 -100.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Selecta Biosciences. More…

    Operations Investing Financing
    -26.16 3.66 -1.82
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Selecta Biosciences. More…

    Total Assets Total Liabilities Book Value Per Share
    139.51 74.06 0.43
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Selecta Biosciences are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    94.1% -66.7%
    FCF Margin ROE ROA
    -55.3% -29.0% -14.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we analyze a company’s financials to help investors make informed decisions. For SELECTA BIOSCIENCES, we have given them a low health score of 3/10 due to their cashflows and debt. This means they are less likely to ride out any crisis without the risk of bankruptcy. When it comes to their performance metrics, SELECTA BIOSCIENCES is strong in asset, growth, and medium in profitability and weak in dividend. We classify SELECTA BIOSCIENCES as a ‘rhino’, meaning they have achieved moderate revenue or earnings growth. This type of company may be of interest to investors looking for moderate returns with reduced risk. However, investors should be aware of the potential for SELECTA BIOSCIENCES to face significant cashflow and debt issues which could lead to bankruptcy and should do their own research before investing. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s primary competitors are Alpine Immune Sciences Inc, Adocia, and IMV Inc. All three companies are engaged in the development of similar therapeutics and vaccines. Selecta has a strong focus on developing its therapeutics for the treatment of cancer and autoimmune diseases. The company’s competitors are also focused on these therapeutic areas.

    However, Selecta has a unique approach to developing its therapeutics that sets it apart from its competitors.

    – Alpine Immune Sciences Inc ($NASDAQ:ALPN)

    Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company, which focuses on developing immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases. The company’s products include ALPN-101 and ALPN-202. Alpine Immune Sciences Inc was founded by Mitchell H. Gold in September 2002 and is headquartered in Seattle, WA.

    – Adocia ($OTCPK:ADOIF)

    Adocia is a French pharmaceutical company that specializes in the development of insulin therapies. The company has a market cap of 30.9M as of 2022 and a Return on Equity of 33.93%. Adocia’s products are designed to improve the lives of patients with diabetes by providing them with more efficient and convenient treatments. The company’s products are available in over 60 countries and have been used by millions of patients worldwide.

    – IMV Inc ($TSX:IMV)

    IMV Inc is a biopharmaceutical company that focuses on the discovery and development of cancer immunotherapies. The company’s market cap is $39.99M and its ROE is -370.99%. IMV Inc’s main product is a cancer immunotherapy that uses the body’s own immune system to fight cancer cells. The company’s products are currently in clinical trials and have shown promising results in early stage trials.


    SELECTA BIOSCIENCES reported disappointing financial results for the second quarter of their fiscal year 2023. Total revenue declined by 86.6% to $5.2 million compared to the same period in the prior year, while net income fell 8.6 million to a loss of $11.4 million. Investors may be cautious in evaluating SELECTA BIOSCIENCES’s future prospects, given its weak performance in the second quarter and the uncertain economic environment. However, its strong balance sheet and cash position may provide a cushion against further losses.

    Recent Posts

    Leave a Comment